Connie Baum Newman, MD, FACP, FAHA, FAMWA
Adjunct Professor of Medicine, NYU School of Medicine
AMWA President 2018-2019
Co-Chair: Obesity and Weight Management Task Force
Co-Chair: Opioid Addiction in Women Task Force
Connie B. Newman, MD is an endocrinologist and Adjunct Professor of Medicine at New York University School of Medicine and Academic Visitor at the University of Oxford, UK. She is the 2018-2019 President of the American Medical Women’s Association. Dr. Newman is Board certified in Internal Medicine, and Endocrinology and Metabolism. She is also certified by the American Board of Obesity Medicine. She is an attending physician in the MOVE Weight Management Clinic at the New York Harbor VA Hospital in New York City.
Dr. Newman’s interests include cardiovascular risk factors, lipids, obesity, and sex differences in disease. She has developed numerous symposia on obesity medicine for endocrinologists and is currently working with the Obesity and Weight Management Committee of the AMWA Preventive Medicine Task Force (PMTF) on a webinar for physicians about obesity, its pathophysiology and management. She serves on the Obesity Medical Education Collaboration (OMEC), a collaboration led by The Obesity Society, the Obesity Medical Association and the Society of Metabolic and Bariatric Surgery. As a member of OMEC she contributed to the development of competencies and benchmarks for a medical school curriculum on obesity.
Dr. Newman is an FDA appointed consultant to the Endocrine and Metabolic Drugs Advisory Committee. She has extensive clinical and research experience in drug safety, and hypercholesterolemia and its relationship to atherosclerotic cardiovascular disease. She designed, conducted and analyzed several large long term cardiovascular outcome trials of statins and is a member of the Cholesterol Treatment Trialists’ Collaboration (CTTC), a select international group of academic physicians with expertise in randomized controlled trials (RCTs). The CTTC conducts meta-analyses of data from the large, long term cardiovascular outcomes trials of lipid lowering medications, primarily statins. Dr. Newman co-authored the paper reporting the meta-analysis on cancer events and cancer mortality in 170,000 patients in 27 statin RCTS. She was a member of the Steering Committee of the groundbreaking Collaborative Atorvastatin Diabetes Study which showed that atorvastatin prevents coronary heart disease and stroke in people with type 2 diabetes.
Over many years, Dr. Newman has written numerous papers on statin safety, statin intolerance, and the nocebo effect. She is the lead author of an extensive review of statin safety which was accepted for publication in 2018. She chairs the Writing Committee for the Endocrine Society Clinical Practice Guideline on the management of dyslipidemia in people with endocrine disorders. She is also a member of the Steering Committee of the Clinical Endocrine Update course of the Endocrine Society. She previously chaired the Special Programs Committee.
Her interest in sex differences in disease has led to the development of The Opioid Addiction in Women Task Force of the PMTF. This task force focuses on education about special issues in women who are addicted to opioids, and recommendations to reduce addiction and its adverse outcomes.
She has long had an interest in family planning and serves on the Board of Directors of Planned Parenthood of Northern, Central and Southern New Jersey as well as the National Medical Committee of the Planned Parenthood Federation of America (PPFA). She is a member of the PPFA Global Advisory Board.
Dr. Newman is a graduate of Weill Cornell Medical College (1978) and Wellesley College (1974), where she was a Durant Scholar and a Trustee Scholar, and elected to Phi Beta Kappa in 1973. She is married and has three children.